<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182791</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1245</org_study_id>
    <nct_id>NCT02182791</nct_id>
  </id_info>
  <brief_title>Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE) and Ethinyl Estradiol/Norethindrone in HIV-1 Infected Women</brief_title>
  <official_title>An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE® ) and Ethinyl Estradiol/Norethindrone [ORTHO-NOVUM® 1/35 (21 Pack)] in HIV-1 Infected Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the effects of nevirapine treatment on the pharmacokinetics of ethinyl
      estradiol (EE)/norethindrone (NET).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <primary_completion_date type="Actual">April 1999</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (Area under the plasma concentration time curve) of ethinyl estradiol/norethindrone (EE/NET)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 0 and day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum observed concentration) of EE/NET</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 0 and day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (Time of maximum concentration) of EE/NET</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 0 and day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCss (Area under the concentration time curve at steady state) of nevirapine</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum observed concentration) of nevirapine</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin (minimum observed concentration) of nevirapine</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cl/F (Oral clearance) of nevirapine</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 59 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Nevirapine tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once a day (q.d.) Day 2-15,
twice a day (b.i.d.) Study day 16-30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EE/NET tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose on Study Day 0 and 30</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <arm_group_label>Nevirapine tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE/NET</intervention_name>
    <arm_group_label>EE/NET tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients between the ages of 18 and 65 years

          -  Plasma HIV-1 RNA &lt;= 400 copies/mL, documenting HIV-1 infection, within 28 days prior
             to Study Day 0

          -  Lymphocytes Expressing CD4+ Surface Marker (CD4+ cell count) &gt;= 100 cells/mm³ within
             28 days prior to Study Day 0

          -  Patients who meet the following laboratory parameter:

               -  Lymphocyte count &gt;= 1000 cells/mm³

               -  Hemoglobin &gt;= 9.0 g/dl (men and women)

               -  Platelet count &gt;= 75000 cells/mm3

               -  Alkaline Phosphatase &lt;= 3.0 times the upper limit of normal

               -  Serum Glutamic-Oxaloacetic Transaminase (SGOT) and Serum Glutamic-Pyruvic
                  Transaminase (SGPT) &lt;= 3.0 times the upper limit of normal

               -  Total bilirubin &lt;= 1.5 times the upper limit of normal

               -  Creatinine &lt;= 2mg/dL

          -  Female patients of reproductive potential must be willing to use a reliable method of
             double-barrier contraception (such as diaphragm with spermicidal cream or jelly, or
             condoms with spermicidal foam)

          -  Patients who are informed of and willing and able to comply with the investigational
             nature of the study and had signed a written consent in accordance with institutional
             and federal guidelines

          -  Patients who have been on stable antiretroviral therapy (no changes in medication or
             dose) for at least thirty days prior to study entry and who will continue on
             background during study participation

        Exclusion Criteria:

          -  Female patients who are pregnant or breast-feeding

          -  Patients requiring systemic treatment with corticosteroids or drugs known to be
             hepatic enzyme inducers or inhibitors within 14 days of stud entry (Study Day 0). Such
             substances in these categories include: macrolide antibiotics (erythromycin,
             clarithromycin), azole antifungals (ketoconazole, fluconazole, itraconazole) rifampin,
             rifabutin, and phenytoin

          -  Patients receiving any investigational drug within 30 days of the first dose of study
             medication and any antineoplastic agent or radiotherapy other than local skin
             radiotherapy treatment within 12 weeks before starting study medication

          -  Patients with malabsorption, severe chronic diarrhea or patients unable to maintain
             adequate oral intake

          -  Patients with a history of intravenous drug abuse, alcohol or substance abuse
             considered by the Investigator and Boehringer Ingelheim Pharmaceutical Incorporated
             (BIPI) Medical Monitor to be a significant impairment to health and compliance

          -  Patients undergoing treatment for an active infection

          -  Patients with hepatic insufficiency due to cirrhosis

          -  Patients with renal insufficiency

          -  Patients who are heavy smokers (e.g. &gt; 20 cigarettes per day)

          -  Patients currently taking Norvir® (Ritonavir) or Rescriptor® (Delavirdine)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Mestranol</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
    <mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
    <mesh_term>Norinyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

